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Abstract
The aim of the study was to evaluate the relationship between cholesterol contained in very-low-density lipoproteins (VLDL-C),
intermediate-density lipoproteins (IDL-C), low-density lipoproteins, high-density lipoproteins, and carotid intima–media thick-
ness (cIMT) and carotid plaques in 228 postmenopausal women (63.1+ 8.2 years) who participated in the ATENA Project and
underwent clinical, biochemical (including the assay of lipoproteins using the Lipoprint system), and carotid ultrasound tests. Very-
low-density lipoprotein cholesterol had a statistically significant linear association with cIMT (P < .001), which remained significant
after adjustment for age, smoking, systolic blood pressure, glucose, and body mass index (r2¼ .20, P < .05). Higher concentrations
of IDL-C and cholesterol contained in triglyceride-rich lipoproteins (TRL-C, ie, VLDL-Cþ IDL-C) were associated with plaques in
the common carotid (tertile III/tertile I: odds ratio [OR]¼ 2.52, 95% confidence interval [CI]¼ 1.21-5.32, P < .02; OR¼ 2.30, 95%
CI ¼ 1.05-5.01, P < .05, respectively), after adjustment for main cardiovascular risk factors. In conclusion, high concentrations of
VLDL-C and TRL-C are independently associated with the presence of carotid plaques. Their assay represents a useful tool for
improving our knowledge on the role of different classes of lipoproteins in atherosclerosis.
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Introduction
Plasma cholesterol is now established as a risk factor for car-
diovascular disease (CVD).1 A reduction in total cholesterol
and low-density lipoprotein cholesterol (LDL-C) is associated
with a lower risk of both coronary heart disease and stroke.2,3
Nevertheless, patients who undergo cholesterol-lowering treat-
ment and reach a specified LDL-C target are still at risk of
mortality and morbidity due to CVD (residual risk).4 A role
is played by other known CVD risk factors (eg, diabetes, arter-
ial hypertension, cigarette smoking, and obesity). Nevertheless,
it is likely that other lipids, in addition to LDL-C, also play a
role in determining this residual risk.
Epidemiological evidence from univariate analyses has
highlighted the importance of triglycerides (TG) and high-
density lipoprotein cholesterol (HDL-C) as risk factors for
CVD.5,6 However, in other studies, TG and HDL-C lost their
role as “independent” risk factors owing to the correction for
other cardiovascular risk factors (in particular body mass index
[BMI] and hyperglycemia) and also since there is a strong
inverse association between these 2 lipid variables. Moreover,
several trials failed to demonstrate any clinical advantage of
increasing HDL-C or reducing TG.7,8
Many expert guidelines and other studies have recognized
apolipoprotein B (apoB) and non-HDL-C levels as better pre-
dictors of cardiovascular risk compared with LDL-C, particu-
larly among postmenopausal women.9,10 The excess risk of
CVD and atherosclerosis captured by apoB or non-HDL-C
suggests a need for more precision when measuring TG-rich
lipoproteins (TRLs) levels and their association with ultra-
sound markers of atherosclerosis. In the fasting state, TRLs
consist of very-low-density lipoprotein (VLDL) and
intermediate-density lipoprotein (IDL) concentrations and
could be estimated with advanced lipoprotein testing.
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In a recent study, a fraction of VLDL cholesterol (VLDL3-C)
plus IDL-C concentrations were associated with a risk of inci-
dent coronary heart disease in 2 diverse, prospective, longitudi-
nal observational US cohorts (Jackson Heart Study and
Framingham Offspring Cohort Study).11
The Lipoprint system is a method based on the prestaining
of serum lipid fractions with Sudan black and on the subse-
quent 3% nondenaturing polyacrylamide gel gradient electro-
phoresis.12,13 It provides information on the distribution of
lipoproteins and measures the levels of esterified cholesterol
in each fraction. This method separates up to 12 lipoprotein
fractions (1 VLDL, 3 IDLs, 7 LDLs, and 1 HDL) of cholesterol
of decreasing size and increasing density and electrophoretic
mobility. The inter- and intra-assay coefficients of variation for
the 12 subfractions were <10%.
Carotid intima–media thickness (cIMT) is the most studied
and used surrogate marker for systemic atherosclerosis. The
cIMT is a predictor of cardiovascular events, and an increase
in cIMT in the common carotid (CC) artery is associated with
an increased risk of stroke and acute myocardial infarction.14-16
Compared with premenopausal women, postmenopausal
women have a more atherogenic lipid profile, with higher con-
centrations of total cholesterol, LDL-C, and TG and lower
HDL2-C.
17-19 In addition to these major lipid abnormalities,
modifications in size and density of the lipoproteins happen
after menopause. Small and dense LDLs (sdLDLs) are more
frequent in postmenopausal women, while larger and buoyant
LDLs are decreased.20 The lack of estrogen after menopause
could contribute to hypertriglyceridemia, low HDL-C, and a
predominance of sdLDLs.21 These lipid changes after meno-
pause could partly explain the increased cardiovascular risk in
postmenopausal women.22
The objective of this study was to evaluate the relationship
between cholesterol contained in VLDL, IDL, LDL, and HDL,
calculated using the Lipoprint method, and cIMT and carotid
plaques in women of postmenopausal age.
Methods
The Progetto ATENA (ATENA project) is an epidemiological
investigation with the aim of studying the environmental, bio-
logical, and genetic causes of the major chronic degenerative
diseases in women.23 Between 1993 and 1996, a total of 5062
women, aged between 30 and 69 years, and free of any known
diseases, participated in the study. Approximately 400 of
these women were randomly selected from the City of
Naples’ registry lists. The remaining women responded
voluntarily to the call made through information campaigns.
All participants signed a specific informed consent form. The
study was approved by the ethics committee of the institu-
tions involved. Approximately 10 years since the first visit,
228 women, randomly chosen from the eldest and all post-
menopausal, were recalled and underwent clinical, biochem-
ical, and ultrasound tests. Our study is based on the data
deriving from these investigations including the assay of
lipoproteins using the Lipoprint system.
The BMI was used as an obesity indicator. Systolic blood
pressure (SBP) and diastolic blood pressure at rest were mea-
sured 2 times after an interval of 5 minutes using a random
zero sphygmomanometer, and the average of those measure-
ments was used in statistical analyses. A standard questionnaire
was used to gather information regarding smoking habits. Eight
women were taking hormone therapy at the time of the visit.
Twenty-six individuals were taking lipid-lowering drugs.
Blood samples were collected after 12 to 14 hours of fasting,
from 8:00 to 9:30 in the morning, and biochemical analyses were
performed on fresh blood samples (serum), whereas measure-
ments of the cholesterol content in each lipoprotein subfractions
were performed with the Lipoprint system (Quantimetrix Inc,
Redondo Beach, California) on frozen serum samples (80C)
within 5 years from blood collection. The concentrations of total
cholesterol and TG were measured using standard enzymatic
methods. High-density lipoprotein cholesterol was measured
after a precipitation of very-low-density and of low-density lipo-
proteins with phosphotungstic acid, and LDL-C was calculated
using the Friedewald equation.24 Non-HDL cholesterol was cal-
culated as total cholesterol  HDL-C. Fasting glucose levels
were determined enzymatically with the peroxidase method.
Fasting insulin levels were determined using an immunoenzy-
matic assay (Ultrasensitive Insulin Elisa; Mercodia, Uppsala,
Sweden). Both ApoB and high-sensitivity C-reactive protein
were measured using an automated turbidimetric method
(Cobas-Mira, Roche, Italy). The insulin resistance index
(homeostatic model assessment) was calculated using the for-
mula by Matthews et al.25
The high-resolution B-mode carotid ultrasound examination
was performed by an expert sonographer using a Esaote AU4
(Biosound Esaote, Inc, Indianapolis, Indiana). The sonographer
was blinded to the participants’ biomarker data. Measurements
were taken on the anterior and posterior wall of the distal seg-
ment (equal to 1 cm) of the CC artery on both sides. At each
examination, the sonographer used different scanning angles
(anterior, lateral, and posterior) to identify the maximum thick-
ness of the cIMT for each wall, following a standardized proto-
col. The images were recorded for subsequent analyses.26 The
CC T-max was defined as the maximum cIMT value measured
between all CC walls on each side (single value). Differently
from other measures of cIMT, CC T-max better reflects the
severity than the extension of the arterial disease. In particular,
in this study, a CC T-max value 1.2 mm (CC T-max median)
in addition to luminal protrusion of 50% in relation to the neigh-
boring walls was considered as CC plaque. It was possible to
take IMT measurements for the CC in all of the 228 participants
recruited for the study. Continuously monitored quality control
data indicated a coefficient of reproducibility for IMT of the CC
of 0.85. This parameter includes the variability of the medical
equipment, sonographer, and reader.27
Statistical Analysis
This was carried out using version 19.0 of the SPSS program
(SPSS, Inc, Chicago, Illinois). The continuous variables were
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described as mean and standard deviation. Linear regression
analysis was used to compare the association among cIMT
and lipoprotein subfractions (continuous variables). Subse-
quently, the HDL-C, LDL-C, IDL-C, and VLDL-C values
measured with the Lipoprint system were stratified by tertiles,
and logistic regression analyses were used to test the relation-
ship between the tertiles of these lipid parameters and the
presence of plaque in the CC. Main cardiovascular risk fac-
tors, such as age, smoking, blood pressure, glycaemia,
HDL-C, and BMI, were added as covariates. A 2-tailed
P < .05 was considered significant.
Results
The demographic, clinical, and biochemical characteristics of
the studied women are shown in Table 1. It should be remem-
bered that the Friedewald calculation of LDL-C (Table 1) is not
only an indirect value but also includes lipoprotein(a) choles-
terol and IDL-C values.
Women with carotid plaques were older and had higher
concentrations of total cholesterol, TG, apoB, non-HDL-C, and
SBP. In a linear regression analysis, VLDL-C (Pearson r ¼
.26, P < .001), IDL-C (r ¼ .16, P ¼ .021), VLDL-C þ IDL-C
(r ¼ .25, P < .001), and LDL-C (r ¼ .14, P ¼ .036) had a
positive and significant correlation with the continuous vari-
able CC T-max. The association was confirmed for VLDL-C
after correction for the principal confounding cardiovascular
risk factors (Table 2).
The results of the Lipoprint assay of cholesterol contained in
different lipoprotein subfractions are shown in Table 3.28 The
LDL subfraction 1 indicates large LDL particles, 2 represents
intermediate, and 3 to 7 means small. In univariate analysis,
there was a correlation between the cholesterol contained in
TRLs and sdLDLs (r ¼ .44, r2 ¼ .20, P < .001).
In a logistic regression analysis, higher tertiles of VLDL-C,
IDL-C, VLDL-C þ IDL-C, and LDL-C were associated with
the presence of carotid plaques. After adjustment for the main
cardiovascular risk factors, the highest tertile of IDL-C (odds
ratio [OR]: 2.52, 95% confidence interval [CI]: 1.24-5.32, P <
.02) and TRL-C (OR: 2.30, 95% CI: 1.05-5.01, P < .05) proved
to be significantly correlated with the presence of plaques in the
CC artery (Table 4). These results did not substantially change
when we added sdLDL concentration in the model: Highest
tertiles of IDL-C and TRL-C showed an association with
Table 1. Clinical Characteristics of Participants Without Plaques






Age, years, range 60.8 (8.1), 43-78 66.2 (7.2), 48-810 <.001
BMI (kg/m2) 27.9 (4.6) 28.5 (4.7) .36
Total cholesterol (mg/dL) 217 (38) 233 (38) .001
Triglycerides (mg/dL) 103 (53) 122 (61) .015
HDL-C (mg/dL) 58 (13) 57 (13) .35
LDL-C (mg/dL) 138 (33) 152 (34) .002
Apo-B (mg/dL) 1.1 (0.2) 1.2 (0.2) .001
Non-HDL-C (mg/dL) 158 (38) 177 (40) .001
Glucose (mg/dL) 103 (18) 109 (32) .12
HOMA 1.7 (1.2) 1.9 (1.4) .20
SBP (mm Hg) 139 (20) 149 (22) <.001
DBP (mm Hg) 81 (9) 82 (8) .44
Ln-CRP (units) 0.4 (1.1) 0.4 (1.0) 0.62
Smoking, n (%)
Current 43 (33) 35 (35) .94
Ex 26 (20) 20 (20)
Never 60 (47) 44 (44)
Abbreviations: apoB, apolipoprotein B; BMI, body mass index; DBP, diastolic
blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA, homeo-
static model assessment; LDL-C, low-density lipoprotein cholesterol; Ln-CRP,
logarithm of high-sensitivity C-reactive protein; SBP, systolic blood pressure;
SD, standard deviation.
aValues are means (SD). Smoking is expressed as absolute numbers and per-
centage (in brackets).
Table 2. Association Between Cholesterol Contained in the Various
Lipoprotein Fractions (Lipoprint) and CC T-Max After Adjustment for
the Main CV Risk Factors (Linear Regression).a
Variable b 95% CI P
HDL-C .00154 0.00491 to 0.00183 .37
LDL-C .00155 0.00033 to 0.00342 .11
IDL-C .00138 0.00154 to 0.00431 .35
VLDL-C .00336 0.00010 to 0.00662 .043
TRL-C .00176 0.00016 to 0.00367 .072
Abbreviations: CC T-max, maximum intima–media thickness measured as a
continuous variable between all the common carotid artery walls; CI,
confidence interval; CV, cardiovascular; HDL-C, high-density lipoprotein
cholesterol; IDL-C, intermediate-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; TRL-C, triglyceride-rich lipoprotein
cholesterol; VLDL-C, very-low-density lipoprotein cholesterol.
aAdjusted for age, systolic blood pressure (SBP), glucose, smoking, and body
mass index (BMI).









VLDL, mg/dL 29.1 (13.7) <22 22-31 >31
IDL (C), mg/dL 19.3 (6.2) <17 17-21 >21
IDL (B), mg/dL 16.4 (7.0) <14 14-18 >18
IDL (A), mg/dL 21.2 (7.3) <18 18-23 >23
Total IDL (C þ B þ A),
mg/dL
56.8 (14.4) <50 50-62 >62
VLDL þ IDL, mg/dL 85.9 (23.0) <75 75-92 >92
Large LDL (1), mg/dL 47.9 (14.4) <41 41-53 >53
Intermediate LDL (2), mg/dL 25.7 (12.8) <19 19-32 >32
Small LDL (3-7), mg/dL 3.4 (6.8) 0 0-3 >3
Total LDL (1-7), mg/dL 77.1 (22.6) <67 67-87 >87
HDL, mg/dL 60.9 (13.5) <54 54-65 >65
Abbreviations: HDL, high-density lipoproteins; IDL, intermediate-density lipo-
proteins; IDL (C, B, A), progressively smaller intermediate-density lipoproteins;
LDL, low-density lipoproteins; LDL (1, 2, 3-7), progressively smaller low-density
lipoproteins; SD, standard deviation; VLDL, very-low-density lipoproteins.
an ¼ 228.
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carotid plaques (OR: 2.66, 95% CI: 1.26-5.62, P < .02; OR:
2.50, 95% CI: 1.12-5.56, P < .05, respectively).
Discussion
The present study demonstrated a linear, statistically signif-
icant and positive association between the cholesterol of the
VLDL lipoproteins and cIMT, after adjustment for the main
CV risk factors. High concentrations of cholesterol con-
tained in IDLs and TRLs were associated with plaques in
the CC artery even after correction for the main risk factors
for CVD.
A sizeable proportion of CV events occurs in participants
who have LDL-C levels in the range of normal values.29 It has
been hypothesized that some of this increased risk is due to
other atherogenic lipoproteins (VLDL particles and IDL) or
their subfractions.30 A variety of lipoprotein assays have been
developed that subfractionate lipoprotein particles according to
their size, density, or charge. The number and nomenclature of
lipoprotein subfractions are not uniform across the different
techniques and have not been standardized, making it difficult
to compare results from various tests.31
In the JUPITER trial, baseline LDL-C was not associated
with CVD events, in contrast with significant associations for
atherogenic particles and subfractions of VLDL and LDL par-
ticles.32 Several lines of evidence demonstrate a significant
association of sdLDLs with increased CVD risk.33,34
There are few published studies on the association between
cholesterol of different lipoprotein fractions and cIMT. The
present article focuses on the relationship between TRLs con-
centration and cIMT; however, our group demonstrated, in the
same patients enrolled in the present study, a significant asso-
ciation between sdLDLs, measured using the Lipoprint system,
and the cIMT. This association was maintained even after
adjustment for age and apoB.35 The LDL subclass phenotypes
may result from interaction of multiple genetic and environ-
mental determinants. In view of the close relationship of
change in plasma TG, apoB, VLDL, and IDL concentrations
with change in LDL particle size and with generation of
sdLDLs, it is likely that both genetic and nongenetic factors
could involve effects on metabolism of plasma TRLs and
sdLDLs. In the present study, there was a significant correla-
tion between the cholesterol contained in TRLs and sdLDLs.
However, the association between carotid plaques and highest
tertiles of TRLs did not substantially change after adjustment
for sdLDL concentration.
In a Japanese study conducted among apparently healthy
men, the only lipoprotein fractions (measured using High Per-
formance Liquid Chromatography) associated with cIMT were
the “small” VLDL-C and the “large” and “very small” LDL-C.
No association was present for HDL-C.36 In a study on 156
men in apparent good health, conducted in Milan, the concen-
trations of cholesterol in TRLs and sdLDLs proved to be inde-
pendent predictors of cIMT and were associated with
monocytic and endothelial pro-inflammatory activation.37
In the MARS study, IDLs were the only lipoproteins found
to be significantly correlated with cIMT progression.38 In a
recent study, atherogenic lipoprotein particle concentrations
were associated with CVD risk when LDL-C was low. Among
individuals with the lowest LDL-C on statin therapy, the smal-
lest subclass of VLDL was strongly associated with residual
risk, and this risk was related to the cholesterol carried in
VLDL.39 It seems plausible that the cholesterol content of
VLDLs was causal for atherosclerosis development, by accu-
mulation in the arterial wall. Finally, in a study conducted, like
ours, among postmenopausal women, the calcium content of
the coronary arteries was associated with VLDLs and sdLDLs,
but not with LDLs, and these results were confirmed even
after adjustment for age, smoking, arterial pressure, TG, and
HDL-C.40 Therefore, in the studies in which the different
classes of lipoproteins were measured and not calculated, the
lipoprotein fractions most often associated with atherosclerosis
were VLDLs, IDLs, and sdLDLs and not LDLs or HDLs.
The limitations of our study need to be acknowledged. The
study population consists of a relatively small number of post-
menopausal women. The cross-sectional nature of the current
findings does not allow inference of causality. Additional stud-
ies are needed to understand prospectively the role of specific
lipoprotein subfractions in the development of carotid athero-
sclerosis in postmenopausal women.
In conclusion, the present cross-sectional study suggests that
in menopausal women the concentrations of VLDL-C are
Table 4. Association Between Tertiles of Lipoprotein Subfractions and Carotid Plaques After Adjustment for the Main CV Risk Factors
(Logistic Regression).a
Variable
Tertile II (n ¼ 78) vs Tertile I (Reference; n ¼ 73) Tertile III (n ¼ 77) vs Tertile I (Reference; n ¼ 73)
OR 95% CI P OR 95% CI P
HDL-C 1.41 0.89-3.01 .37 0.83 0.38-1.81 .63
LDL-C 1.99 0.92-4.27 .29 2.11 0.97-4.91 .13
IDL-C 1.29 0.60-2.76 .51 2.52 1.21-5.32 .014
VLDL-C 1.57 0.74-3.33 .19 1.64 0.75-3.57 .26
TRL-C 1.88 0.86-4.11 .08 2.30 1.05-5.01 .037
Abbreviations: CI, confidence interval; CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; IDL-C, intermediate-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; TRL-C, triglyceride-rich lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol.
aAdjusted for age, systolic blood pressure (SBP), glucose, smoking, and body mass index (BMI).
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linearly and directly correlated with cIMT, independently of
the main risk factors for CVD and that high concentrations of
IDL-C and TRL-C are independently associated with the
presence of carotid plaques. Their assay therefore represents
a useful tool for improving our knowledge on the role of spe-
cific lipoprotein subfractions in the development of carotid
atherosclerosis in postmenopausal women.
Authors’ Note
All authors made substantial contributions to conception and design,
acquisition of data, or analysis and interpretation of data; drafting the
article or revising it critically for important intellectual content; and
final approval of the version to be published.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: The “Progetto
Atena” was supported by funds from the Consiglio Nazionale delle
Ricerche (Rome, Italy), “Progetto finalizzato Biotecnologie,” and
“Progetto finalizzato FATMA”; the Ministero dell’Universita` e della
Ricerca Scientifica e Tecnologica, “Progetto Ricerche Interesse




1. National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults (Adult Treatment Panel III) final report. Circula-
tion. 2002;106(25):3143-421.
2. Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Commit-
tee of the National Cholesterol Education Program. Implications
of recent clinical trials for the National cholesterol education
program adult treatment panel III guidelines. Arterioscler Thromb
Vasc Biol. 2004;24(8):e149-61.
3. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment
Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-
lowering treatment: prospective meta-analysis of data from
90,056 participants in 14 randomised trials of statins. Lancet.
2005;366(9493):1267-78.
4. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or
Atorvastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 Investigators. Intensive versus moderate
lipid lowering with statins after acute coronary syndromes. N
Engl J Med. 2004;350(15):1495-04.
5. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the
risk of coronary heart disease: 10,158 incident cases among
262,525 participants in 29 Western prospective studies. Circula-
tion. 2007;115(4):450-8.
6. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-
cholesterol and risk of stroke and carotid atherosclerosis: a sys-
tematic review. Atherosclerosis. 2008;196(1):489-96.
7. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Inves-
tigators. Effects of torcetrapib in patients at high risk for coronary
events. N Engl J Med. 2007;357(21):2109-22.
8. Keech A, Simes RJ, Barter P, et al; FIELD study investigators.
Effects of long-term fenofibrate therapy on cardiovascular
events in 9795 people with type 2 diabetes mellitus (the FIELD
study): randomised controlled trial. Lancet. 2005;366(9500):
1849-61.
9. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of
low-density lipoprotein cholesterol, non-high-density lipoprotein
cholesterol, and apolipoprotein B as markers of cardiovascular
risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-45.
10. Shai I, Rimm EB, Hankinson SE, et al. Multivariate assessment
of lipid parameters as predictors of coronary heart disease
among postmenopausal women: potential implications for
clinical guidelines. Circulation. 2004;110(18):2824-30.
11. Joshi PH, Khokhar AA, Massaro JM, et al; Lipoprotein Investi-
gators Collaborative (LIC) Study Group. Remnant lipoprotein
cholesterol and incident coronary heart disease: the Jackson Heart
and Framingham Offspring Cohort Studies. J Am Heart Assoc.
2016;5(5):e002765.
12. Gentile M, Panico S, Jossa F, et al. Small dense LDL particles and
metabolic syndrome in a sample of middle-aged women. Findings
from progetto atena. Clin Chim Acta. 2008;388(1-2):179-83.
13. Hoefner DM, Hodel SD, O’Brien JF, et al. Development of a
rapid, quantitative method for LDL subfractionation with use of
the quantimetrix lipoprint LDL system. Clin Chem. 2001;47(2):
266-74.
14. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Predic-
tion of clinical cardiovascular events with carotid intima-media
thickness: a systematic review and meta-analysis. Circulation.
2007;115(4):459-67.
15. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-
media thickness and cardiovascular events. N Engl J Med. 2011;
365(3):213-21.
16. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE.
Common carotid intima-media thickness and risk of stroke and
myocardial infarction: the rotterdam study. Circulation. 1997;
96(5):1432-37.
17. Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF.
Effects of menopause, gender and age on lipids and high-density
lipoprotein cholesterol subfractions. Maturitas. 2015;81(1):
62-68.
18. Kolovou GD, Bilianou HG. Influence of aging and menopause on
lipids and lipoproteins in women. Angiology. 2008;59(suppl 2):
54S-7S.
19. Stevenson J, Crook D, Godsland I. Infuence of age and meno-
pause on serum lipids and lipoproteins in healthy women.
Atherosclerosis. 1993;98(1):83-90.
20. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ.
Differences in low density lipoprotein subfractions and apolipo-
proteins in premenopausal and postmenopausal women. J Clin
Endocrinol Metab. 1988;67(1):30-35.
Iannuzzi et al 5
21. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal
metabolic syndrome? Gynecol Endocrinol. 1997;11(5):341-55.
22. Fonseca MIH, da Silva IT, Ferreira SRG. Impact of menopause
and diabetes on atherogenic lipid profle: is it worth to analyse
lipoprotein subfractions to assess cardiovascular risk in women?
Diabetol Metab Syndr. 2017;9:22.
23. Panico S, Dello Iacovo R, Celentano E, et al. Progetto ATENA, a
study on the etiology of major chronic diseases in women: design,
rationale and objectives. Eur J Epidemiol. 1992;8(4):601-8.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem. 1972;
18(6):499-502.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model
assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia.
1985;28(7):412-9.
26. De Michele M, Panico S, Iannuzzi A, et al. Association of obesity
and central fat distribution with carotid artery wall thickening in
middle-aged women. Stroke. 2002;33(12):2923-8.
27. Tang R, Hennig M, Thomasson B, et al. Baseline reproducibility
of B-mode ultrasonic measurement of carotid artery intima-media
thickness: the European Lacidipine Study on Atherosclerosis
(ELSA). J Hypertens. 2000;18(2):197-201.
28. Delaye JB, Patin F, Piver E. Low IDL-B and high LDL-1 subfrac-
tion levels in serum of ALS patients. J Neurol Sci. 2017;380:124-7.
29. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be
used as a worthwhile screening test? BMJ. 1999;319(7224):
1562-5.
30. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cho-
lesterol in estimating cardiovascular risk and in guiding therapy:
report of the thirty-person/ten-country panel. J Intern Med. 2006;
259(3):247-58.
31. Mora S. Advanced lipoprotein testing and subfractionation are not
(yet) ready for routine clinical use. Circulation. 2009;119(17):
2396-404.
32. Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic
lipoprotein subfractions determined by ion mobility and first car-
diovascular events after random allocation to high-intensity statin
or placebo: the Justification for the Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Circulation. 2015;132(23):2220-9.
33. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on
low density lipoprotein (LDL) subclasses”: a statement on the
pathophysiology, atherogenicity and clinical significance of
LDL subclasses: executive summary. Curr Vasc Pharmacol.
2011;9(5):531-2.
34. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low
density lipoprotein (LDL) subclasses”: a statement on the
pathophysiology, atherogenicity and clinical significance of LDL
subclasses. Curr Vasc Pharmacol. 2011;9(5):533-71.
35. Gentile M, Panico S, Mattiello A, et al. Association between small
dense LDL and early atherosclerosis in a sample of menopausal
women. Clin Chim Acta. 2013;426:1-5.
36. Takahashi R, Taguchi N, Suzuki M, et al. Cholesterol and trigly-
ceride concentrations in lipoproteins as related to carotid intima-
media thickness. Int Heart J. 2012;53(1):29-34.
37. Norata GD, Raselli S, Grigore L, et al. Small dense LDL and
VLDL predict common carotid artery IMT and elicit an inflam-
matory response in peripheral blood mononuclear and endothelial
cells. Atherosclerosis. 2009;206(2):556-62.
38. Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipo-
proteins and progression of carotid arterial wall intima-media
thickness. Circulation. 1997;95(8):2022-6.
39. Lawler PR, Akinkuolie AO, Chu AY, et al. Atherogenic lipopro-
tein determinants of cardiovascular disease and residual risk
among individuals with low low-density lipoprotein cholesterol.
J Am Heart Assoc. 2017;6(7):e005549.
40. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov
R, Matthews KA. Lipoprotein subclasses and coronary artery
calcium in postmenopausal women from the healthy women
study. Am J Cardiol. 2002;90(8A):71i-6i.
6 Angiology XX(X)
